Acrolein modification of apolipoprotein (apo) E in human very low density lipoprotein (VLDL) was suppressed by ascorbate. Acrolein-modified apoE in VLDL was not taken up by human hepatoma cell whereas unmodified apoE in the presence of ascorbate was taken up. These results suggest that ascorbate can play an important role in maintaining proper lipoprotein metabolism by the antioxidant effect.
It has been suggested that oxidation of low density lipoprotein (LDL) might play a pivotal role in the onset of atherosclerosis. [1] [2] [3] [4] A previous study showed that acrolein, a highly reactive aldehyde formed during the decomposition of lipid hydroperoxides, was produced in LDL oxidation by Cu 2þ and that acrolein preferentially modified lysyl residues of LDL in vitro.
5) Also, acroleinmodified protein was detected in atherosclerotic lesions from a human aorta by immunohistochemical analysis with developed antibodies, and it was found that proteinbound acrolein can be a potential marker of oxidative stress. 6) Apolipoprotein (apo) E in very low density lipoprotein (VLDL), the precursor metabolite of LDL, exhibits a much high affinity for the LDL receptor on peripheral cells and hepatocytes than does apoB-100, another component of VLDL. Thus it plays an important role in the regulation of lipoprotein metabolism. 7) We proposed that the metal-catalyzed oxidative modification of apoE in VLDL might be responsible for impairing its biological functions, although one has yet to show that VLDL oxidation is involved in atherogenesis. 8) We have found that a physiological concentration of ascorbate (30-150 mM), a strong antioxidant in the blood, suppresses lipid peroxidation and apoE oxidation in VLDL. 9) In the present study, we examined the effect of ascorbate on the acrolein modification of apoE in VLDL and the uptake of acrolein-modified VLDL by hepatocytes.
Acrolein was purchased from Tokyo Kasei Kogyo (Tokyo). All other chemicals were of reagent grade. VLDL (density 0.960-1.006 g/ml) was separated from fresh human plasma obtained from a healthy volunteer by the ultracentrifugation method 10) with informed consent after fasting for 12 h. VLDL (100 mg of protein) in 500 ml of Tris-HCl-buffered saline (TBS; pH 7.4) was incubated with acrolein (400 mM) in the presence or absence of ascorbate at 37 C for 12 h. In the case of VLDL oxidation by acrolein, 400 mM diethylenetriaminepentaacetic acid was added to the reaction mixture to prevent VLDL oxidation by contaminating metal ions. Cholesteryl ester hydroperoxides (CE-OOH) were determined by high-performance liquid chromatography (HPLC) with UV detection, as described previously.
11)
Oxidized apoE in VLDL was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), using 10% acrylamide slab gel, 12) and subsequent immunoblotting using rabbit anti-acrolein antisera 6) or goat anti-human apoE antisera (Chemicon International, Temecula, CA). A human hepatoma cell line (HepG2), a rat hepatoma cell line (H4-II-E), and a mouse macrophage cell line (RAW 264.7) were maintained in minimum essential medium (MEM) containing 10% fetal bovine serum (FBS) at 37 C under 5% CO 2 / 95% air. FBS was changed to 10% human lipoprotein deficient serum for 48 h for HepG2 and for 24 h for H4-II-E before each experiment. HepG2, H4-II-E, and RAW 264.7 cells (1 Â 10 7 ) were washed with serum-free MEM once and incubated for 1 h with MEM containing VLDL (50 mg/ml) treated with acrolein (400 mM) or Cu 2þ (50 mM) for 12 h in the absence or presence of 1 mM ascorbate, and then dialyzed against TBS to y To whom correspondence should be addressed. Tel/Fax: +81-836-22-2212: E-mail: nakamura@yamaguchi-u.ac.jp Abbreviations: apo, apolipoprotein; CE-OOH, cholesteryl ester hydroperoxides; LDL, low density lipoprotein; HPLC, high-performance liquid chromatography; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TBS, Tris-HCl-buffered saline; VLDL, very low density lipoprotein remove the remaining free acrolein, Cu 2þ , and ascorbate. After the cells were washed with TBS five times, they were sonicated in TBS containing 5% NP-40 with protease inhibitors (Sigma, St. Louis, MO). After centrifugation, the supernatant (7.5 mg protein) was subjected to SDS-PAGE and immunoblotting for human apoE. Figure 1 shows the effect of ascorbate on the acrolein modification of apoE in VLDL. During incubation of VLDL with authentic acrolein for 12 h, no CE-OOH was produced (data not shown), meaning that auto-oxidation of VLDL did not occur. Immunoblot analyses were performed using anti-apoE antibody (panel A) and antiacrolein antibody (panel B). No modification of apoE was found in VLDL incubated without acrolein for 12 h (data not shown). After incubation of VLDL with acrolein, a smear band was detected at 40-75 kDa (panel A, lane 2) in the absence of ascorbate, whereas native apoE was recognized as a single band (lane 1).
Acrolein-protein adducts were detected in VLDL incubated with acrolein in the absence of ascorbate (panel B, lane 2). The single band between 25 kDa and 37 kDa and the ladder bands between 37 kDa and 50 kDa should be acrolein-modified apoE by comparison with panel A. Acrolein modification of apoE (panels A and B) was suppressed by ascorbate in a dose-dependent manner (lanes 5-7). It has been reported that ascorbate inhibits lipid peroxidation in VLDL.
9) The present data suggest that ascorbate acts not only as a radical scavenger but might also function as an inhibitor of modification of VLDL by acrolein, although the mechanism of this process is yet to be established.
ApoE associates with LDL receptor, LDL receptorrelated protein, and heparan sulfate proteoglycans on the surfaces of hepatocytes, and the binding regions of apoE to them are enriched in basic amino acids. 7) It has been found that the heparin-binding activity of apoE decreases after VLDL oxidation by Cu 2þ , indicating that basic VLDL (100 mg of protein) was modified by 400 mM acrolein in 500 ml of Tris-HCl-buffered saline (TBS, pH 7.4) for 12 h at 37 C. VLDL was subjected to immunoblot analysis using anti-human apoE antibody (A) and anti-acrolein antibody (B). Lane 1, native VLDL; lane 2, no ascorbate; lane 3, 10 mM ascorbate; lane 4, 100 mM ascorbate; lane 5, 200 mM ascorbate; lane 6, 500 mM ascorbate; lane 7, 1000 mM ascorbate. amino acids such as lysine in the binding regions of apoE are damaged by reactive oxygen species. 8) In the present study, we examined the uptake of VLDL incubated with Cu 2þ and acrolein by human hepatocytes (HepG2) and rat hepatocytes (H4-II-E), which can incorporate native human apoE. 13) Treatment of cells with VLDL incubated with Cu 2þ and acrolein did not affect cell viability (data not shown). As shown in Fig. 2A, human apoE 2þ -mediated oxidation of VLDL rather than acrolein-modified apoE, in which the amount of crosslinked apoE (Fig. 1A) appears to be smaller than that by Cu 2þ . 8) These results suggest that oxidized VLDL, which is not incorporated into hepatocytes, might accumulate in the cardiovascular system and bind to macrophages to induce atherogenesis. In addition, our data indicate that ascorbate can play an important role in preventing atherogenesis by suppressing the modification of apoE in VLDL by acrolein.
